lifestyle.marketresearchjournals.com

Author: Optimum Strategic Communications

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

January 8, 2026
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

January 8, 2026
ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access

January 8, 2026
TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman

January 8, 2026
Nucleome Therapeutics nominates first preclinical development candidate

January 7, 2026
Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

January 7, 2026
AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board

January 7, 2026
LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease

January 6, 2026
Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation

January 6, 2026
numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System

December 18, 2025